SCHEMBL14723646

SCHEMBL14723646

C=C(c1nccn1Cc1ccccc1)C(C)C

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.48
NPC1 O15118 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
TDP1 Q9NUW8 1/20 0.46
CYP1A2 P05177 2/20 0.45
CYP2D6 P10635 2/20 0.45
CYP2C19 P33261 2/20 0.45
FDPS P14324 1/20 0.45
OPRD1 P41143 1/20 0.45
OPRK1 P41145 1/20 0.45
LMNA P02545 1/20 0.44
ALDH1A1 P00352 2/20 0.43
HSP90AA1 P07900 1/20 0.43
KMT2A Q03164 3/20 0.43
HSD17B10 Q99714 1/20 0.43
MEN1 O00255 2/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
ALOX12 P18054 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1345858 0.77 RAB9A (0.58) RAB9ANPC1SMN1; SMN2TDP1FDPS
SCHEMBL418384 0.76 RAB9A (0.57) RAB9ANPC1SMN1; SMN2FDPSOPRD1
SCHEMBL13389039 0.75 RAB9A (0.55) RAB9ANPC1SMN1; SMN2FDPSOPRD1
SCHEMBL3313595 0.74 ALDH1A1 (0.59) RAB9ANPC1SMN1; SMN2FDPSOPRD1
SCHEMBL29515990 0.74 RAB9A (0.54) RAB9ANPC1SMN1; SMN2FDPSOPRD1
SCHEMBL13379459 0.73 RAB9A (0.54) RAB9ANPC1SMN1; SMN2TDP1FDPS
SCHEMBL17381155 0.73 RAB9A (0.57) RAB9ANPC1SMN1; SMN2TDP1CYP1A2
SCHEMBL9341301 0.73 TDP1 (0.58) SMN1; SMN2TDP1CYP1A2CYP2D6CYP2C19
SCHEMBL697594 0.73 RAB9A (0.46) RAB9ANPC1SMN1; SMN2FDPSOPRD1
SCHEMBL697826 0.73 RAB9A (0.41) RAB9ANPC1SMN1; SMN2TDP1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383094-B2 inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials BRISTOL-MYERS SQUIBB COMPANY (US) 2013-02-26 US disclosed